Jennewein Biotechnologie GmbH

Jennewein Biotechnologie sues Glycom for patent infringement in Denmark

Share

Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the HMO 2’-fucosyllactose for the first time on the market in 2015.

The Danish company Glycom A/S initially tried to chemically synthesize HMOs, but now imitates the path of biotechnological manufacturing of HMOs as pursued by Jennewein Biotechnologie from the beginning.

“After Glycom failed for a decade to accomplish the chemical synthesis, as well as possible biotechnological attempts to produce HMOs at reasonable costs and in industrially relevant amounts, we became aware by Glycom’s recent EFSA and FSANZ filings that they are imitating Jennewein’s processes and infringing our intellectual property.” said Dr. Stefan Jennewein, CEO of Jennewein Biotechnologie GmbH. “We will enforce our intellectual property rights against Glycom and will not tolerate this outrageous patent infringement.” adds Dr. Andreas Hübel, Director IP of Jennewein Biotechnologie GmbH.

Jennewein Biotechnologie has already obtained a seizure order against Glycom and additional evidence seized which will further substantiate infringement of Jennewein’s European Patent EP 2 896 628 B1, and requested an interlocutory injunction against the manufacturing and offering of Glycom’s  HMO products in Denmark on basis of its Danish utility model DK 2019 00054. “Besides the infringement of said patent, we see a number of additional infringements of our IPRs by Glycom.” said Dr. Andreas Hübel.

About HMOs:          

Human milk oligosaccharides (HMOs) are complex sugar molecules that are only present in breast milk. Excluding water, they are the third most abundant constituent of human milk after fats and lactose. More than 200 structurally different HMOs have been identified.

The most abundant HMO is 2′-fucosyllactose, which is produced by about 80% of all lactating mothers at concentrations of up to 3 g/L.Scientific studies have shown that HMOs, and 2′‑fucosyllactose in particular, have a positive impact on infant development. HMOs are prebiotic, i.e. they specifically promote the growth of beneficial microorganisms, and at the same time they inhibit the growth of pathogens by directly and indirectly preventing colonisation. Jennewein Biotechnologie launched 2′-fucosyllactose onto the global baby food market in 2015, and several infant milk formula around the world now contain 2′-fucosyllactose.

Contacts

Press contact:

Dr. Bettina Gutiérrez
Bettina.gutierrez@jennewein-biotech.de
Tel.:+49 2224 98810 797

About Jennewein Biotechnologie GmbH

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH
Maarweg 32
53619 Rheinbreitbach

+49 / (0)2224 - 998 100http://jennewein-biotech.de

About Jennewein Biotechnologie:

Jennewein Biotechnologie is a leading international industrial biotechnology company with a range of products in the field of human milk oligosaccharides (HMOs) and rare monosaccharides such as L-Fucose and Sialic acid.The company manufactures an extensive portfolio of innovative HMO products, such as 2′‑fucosyllactose, 3′-fucosyllactose, Lacto-N-neotetraose, and lacto-N-tetraose. These rare sugars are used in the food industry (particularly infant milk formulas), the pharmaceutical industry, and the cosmetic industry. The manufacturing process involves state-of-the-art fermentation techniques. In 2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie a license to market 2′-fucosyllactose in the USA. This was followed in 2017 by European Union marketing authorisation under the Novel Food Regulation.

Subscribe to releases from Jennewein Biotechnologie GmbH

Subscribe to all the latest releases from Jennewein Biotechnologie GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Jennewein Biotechnologie GmbH

Jennewein Biotechnologie and Yili Group join forces in China for microbiome research and human milk oligosaccharides to bring innovation to the largest baby food market5.2.2019 11:00:00 EETPress release

-China represents the largest market for baby food globally -Human milk oligosaccharides are key for the development of a healthy infant microbiome Hohhot, China & Rheinbreitbach, Germany - Jennewein Biotechnologie GmbH, the global leader in the research and manufacture of human milk oligosaccharides (HMO),and Inner Mongolia Yili Industrial Group (Yili Group), China’s leading dairy company,announce today the signing of a Memorandum of Understanding on infant microbiome and human milk oligosaccharides, with the goal to develop an innovative infant formula and dairy products specifically tailored to the Chinese market. "After already having introduced human milk oligosaccharides in other world regions, such as the key U.S. market and selected European countries, we are very excited to work with Yili, the domestic market leader for microbiome/baby food in China" statedDr. Stefan Jennewein, CEO and Co-Founder of JenneweinBiotechnologie. "With 50% of the total global market volume (2021e: 7

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom